Karyopharm Therapeutics Inc (NASDAQ: KPTI) is -19.42% lower on its value in year-to-date trading and has touched a low of $0.62 and a high of $1.95 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The KPTI stock was last observed hovering at around $0.70 in the last trading session, with the day’s loss setting it 0.0%.
Currently trading at $0.70, the stock is -6.44% and -15.88% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.41 million and changing -0.90% at the moment leaves the stock -31.65% off its SMA200. KPTI registered -41.92% loss for a year compared to 6-month loss of -49.86%. The firm has a 50-day simple moving average (SMA 50) of $0.82246 and a 200-day simple moving average (SMA200) of $1.019075.
The stock witnessed a -15.10% gain in the last 1 month and extending the period to 3 months gives it a -29.96%, and is -5.36% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.85% over the week and 6.56% over the month.
Karyopharm Therapeutics Inc (KPTI) has around 325 employees, a market worth around $86.90M and $145.67M in sales. Profit margin for the company is -61.72%. Distance from 52-week low is 12.89% and -64.26% from its 52-week high. The company has generated returns on investments over the last 12 months (-149.99%).
The EPS is expected to grow by 40.91% this year
140.0 institutions hold shares in Karyopharm Therapeutics Inc (KPTI), with institutional investors hold 62.72% of the company’s shares. The shares outstanding are 114.92M, and float is at 113.93M with Short Float at 15.73%. Institutions hold 56.69% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 7.65 million shares valued at $6.64 million. The investor’s holdings represent 6.6299 of the KPTI Shares outstanding. As of 2024-06-30, the second largest holder is PALO ALTO INVESTORS LP with 5.1 million shares valued at $4.43 million to account for 4.4192 of the shares outstanding. The other top investors are EVERSEPT PARTNERS, LP which holds 4.99 million shares representing 4.3196 and valued at over $4.33 million, while ADAGE CAPITAL PARTNERS GP, L.L.C. holds 3.7416 of the shares totaling 4.32 million with a market value of $3.75 million.
Karyopharm Therapeutics Inc (KPTI) Insider Activity
The most recent transaction is an insider sale by Mano Michael, the company’s SVP, General Counsel&Secretary. SEC filings show that Mano Michael sold 3,971 shares of the company’s common stock on Sep 04 ’24 at a price of $0.72 per share for a total of $2866.0. Following the sale, the insider now owns 0.27 million shares.
Karyopharm Therapeutics Inc disclosed in a document filed with the SEC on Sep 04 ’24 that Paulson Richard A. (President and CEO) sold a total of 3,667 shares of the company’s common stock. The trade occurred on Sep 04 ’24 and was made at $0.72 per share for $2647.0. Following the transaction, the insider now directly holds 1.14 million shares of the KPTI stock.
Still, SEC filings show that on Sep 04 ’24, Mason Michael (EVP, CFO & Treasurer) disposed off 7,050 shares at an average price of $0.72 for $5089.0. The insider now directly holds 391,054 shares of Karyopharm Therapeutics Inc (KPTI).
